KalVista Pharmaceuticals, Inc.
DE ˙ DB ˙ US4834971032
23,01 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:4XC1 / KalVista Pharmaceuticals, Inc.
InstitutionMillennium Management Llc
ManagerIsrael Englander
Latest Disclosed Ownership1,912,146 shares
Ownership 3.70%
Millennium Management Llc ownership in 4XC1 / KalVista Pharmaceuticals, Inc.

2026-05-01 - Millennium Management Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,912,146 shares of KalVista Pharmaceuticals, Inc. (DE:4XC1). This represents 3.7 percent ownership of the company. In their previous filing dated 2025-12-30 , Millennium Management Llc had reported owning 2,963,699 shares, indicating a decrease of -35.48 percent.

Millennium Management Llc has a history of taking positions in derivatives of the underlying security (4XC1) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-05-01 2026-05-01 13G/A 2,963,699 1,912,146 -35.48 3.70 -37.29
2025-12-30 2025-12-30 13G/A 2,531,010 2,963,699 17.10 5.90 18.00
2025-11-10 2025-11-10 13G 2,531,010 5.00

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:4XC1 / KalVista Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 1,912,146 -984,520 -33.99 38,491 -17.72 0.0160
2026-02-17 2025-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 2,896,666 800,443 38.19 46,781 83.23 0.0197
2025-11-14 2025-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 2,096,223 1,755,594 515.40 25,532 563.14 0.0109
2025-08-14 2025-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 340,629 142,424 71.86 3,851 68.34 0.0019
2025-05-15 2025-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 198,205 198,205 2,287 0.0012
2024-08-14 2024-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -19,329 -100.00 0 -100.00
2024-05-15 2024-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 19,329 19,329 229 0.0001
2023-11-14 2023-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -27,935 -100.00 0 -100.00
2023-08-14 2023-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 27,935 -52,768 -65.39 251 -60.41 0.0001
2023-05-15 2023-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 80,703 -395,548 -83.05 634 -80.30 0.0004
2023-02-14 2022-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 476,251 -1,707 -0.36 3,219 -53.58 0.0018
2022-11-14 2022-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 477,958 377,641 376.45 6,935 602.63 0.0041
2022-08-15 2022-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 100,317 83,169 485.01 987 290.12 0.0006
2022-05-16 2022-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 17,148 17,148 253 0.0001
2022-02-14 2021-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -36,715 -100.00 0 -100.00
2021-11-15 2021-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 36,715 36,715 641 0.0004
2021-05-17 2021-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -28,797 -100.00 0 -100.00
2021-02-16 2020-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 28,797 -33,981 -54.13 547 -30.76 0.0004
2020-11-16 2020-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 62,778 15,316 32.27 790 37.63 0.0010
2020-08-14 2020-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 47,462 47,462 574 0.0008
2020-05-14 2020-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 0 -28,148 -100.00 0 -100.00
2020-02-14 2019-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 28,148 13,929 97.96 501 205.49 0.0006
2019-11-14 2019-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 14,219 4,324 43.70 164 -25.11 0.0003
2019-08-15 2019-06-30 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 9,895 -86,575 -89.74 219 -92.07 0.0003
2019-08-14 2019-06-30 13F LIBERTY MEDIA CORP DELAWARE COM A SIRIUSXM 483497103 386,625 290,155 14,618
2019-05-14 2019-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 96,470 96,470 2,761 0.0041
2019-02-15 2018-12-31 13F/A-1 KALVISTA PHARMACEUTICALS COM 483497103 0 -52,041 -100.00 0 -100.00
2018-11-14 2018-09-30 13F KALVISTA PHARMACEUTICALS COM 483497103 52,041 38,924 296.74 1,151 975.70 0.0014
2018-08-14 2018-06-30 13F KALVISTA PHARMACEUTICALS COM 483497103 13,117 -216,131 -94.28 107 -95.08 0.0001
2018-05-15 2018-03-31 13F KALVISTA PHARMACEUTICALS COM 483497103 229,248 -7,336 -3.10 2,173 -5.81 0.0029
2018-02-14 2017-12-31 13F KALVISTA PHARMACEUTICALS COM 483497103 236,584 236,584 2,307 0.0032
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F KALVISTA PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-17 2025-12-31 13F KALVISTA PHARMACEUTICALS COM Call 23,500 17.50 380 55.97 n/a n/a n/a
2025-11-14 2025-09-30 13F KALVISTA PHARMACEUTICALS COM Call 20,000 244 n/a n/a n/a
2023-11-14 2023-09-30 13F KALVISTA PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-14 2023-06-30 13F KALVISTA PHARMACEUTICALS COM Call 50,000 450 n/a n/a n/a
2023-05-15 2023-03-31 13F KALVISTA PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-02-14 2022-12-31 13F KALVISTA PHARMACEUTICALS COM Call 100,000 676 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-11-14 2025-09-30 13F KALVISTA PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-08-14 2025-06-30 13F KALVISTA PHARMACEUTICALS COM Put 90,000 1,017 n/a n/a n/a
2024-05-15 2024-03-31 13F KALVISTA PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-14 2023-12-31 13F KALVISTA PHARMACEUTICALS COM Put 50,000 612 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.